title: Primary chemotherapy followed by anterior craniofacial resection and radiotherapy for paranasal cancer.
abstract: BACKGROUND
  To study prospectively the activity of primary chemotherapy with cisplatin, fluorouracil and leucovorin (PFL) in patients with paranasal cancer receiving surgery and postoperative radiotherapy.
  
  
  METHODS
  Forty-nine patients, previously untreated, with resectable paranasal carcinoma were enrolled. PFL (leucovorin 250 mg/m2/day for 5 days as a 120 h continuous infusion (c.i.), 5-fluorouracil 800 mg/m2/day from day 2 as a 96 h c.i. and cisplatin 100 mg/m2 day 2 q 3 weeks) was planned for five courses.
  
  
  RESULTS
  Thirty-two patients (65%) completed three or more chemotherapy courses. Two deaths from thrombotic events were observed after the first cycle. Eight cardiac toxicities were recorded during chemotherapy causing treatment discontinuation. Objective response to PFL was observed in 21 patients [43%; 95% confidence interval (CI) 29% to 58%], including four complete responses (CRs) (8%; 95% CI 2% to 20%) and 17 partial responses (PRs) (35%). Pathological complete remission (pCR) was achieved in eight of 49 patients (16%). At 3 years, overall survival was 69% and event-free survival 57%. Overall and event-free survival in patients achieving pCR is 100%.
  
  
  CONCLUSIONS
  PFL is active in paranasal cancer. Patients who attain a pathological complete remission have a favorable prognosis. Cardiovascular complications represent the limiting toxicity. Primary chemotherapy combined with surgery-sparing treatment approaches deserves further investigation.
authors.affiliation: Unit of Medical Oncology A, Istituto Nazionale Tumori, Milan, Italy. lisa.licitra@istitutotumori.mi.it
authors.forename: L
authors.initials: L
authors.lastname: Licitra
authors.forename: L D
authors.initials: LD
authors.lastname: Locati
authors.forename: R
authors.initials: R
authors.lastname: Cavina
authors.forename: I
authors.initials: I
authors.lastname: Garassino
authors.forename: F
authors.initials: F
authors.lastname: Mattavelli
authors.forename: N
authors.initials: N
authors.lastname: Pizzi
authors.forename: P
authors.initials: P
authors.lastname: Quattrone
authors.forename: P
authors.initials: P
authors.lastname: Valagussa
authors.forename: L
authors.initials: L
authors.lastname: Gianni
authors.forename: G
authors.initials: G
authors.lastname: Bonadonna
authors.forename: C L
authors.initials: CL
authors.lastname: Solero
authors.forename: G
authors.initials: G
authors.lastname: Cantu
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D002277:Carcinoma / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery*; D002945:Cisplatin / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D007262:Infusions, Intravenous; D002955:Leucovorin / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D010255:Paranasal Sinus Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery*; D011446:Prospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D002945:Cisplatin; D002955:Leucovorin; D005472:Fluorouracil